Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion.

We present a cohort of 41 patients with osimertinib resistance biopsies, including two with an acquired CCDC6-RET fusion. While RET fusions have been identified in resistant EGFR-mutant NSCLC, their role in acquired resistance to EGFR inhibitors is not well described. To assess the biological implic...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Discov
Hoofdauteurs: Piotrowska, Zofia, Isozaki, Hideko, Lennerz, Jochen K., Gainor, Justin F., Lennes, Inga T., Zhu, Viola W., Marcoux, Nicolas, Banwait, Mandeep K., Digumarthy, Subba R., Su, Wenjia, Yoda, Satoshi, Riley, Amanda K., Nangia, Varuna, Lin, Jessica J., Nagy, Rebecca J., Lanman, Richard B., Dias-Santagata, Dora, Mino-Kenudson, Mari, Iafrate, A. John, Heist, Rebecca S., Shaw, Alice T., Evans, Erica K., Clifford, Corinne, Ou, Sai-Hong I., Wolf, Beni, Hata, Aaron N., Sequist, Lecia V.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2018
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279502/
https://ncbi.nlm.nih.gov/pubmed/30257958
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-18-1022
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items